Although breast cancer risk stratification might not currently be feasible for men in the general population, male BRCA1 and BRCA2 carriers may represent a group likely to benefit from a more refined stratification of their individual breast and prostate cancer risks, to better inform their clinical management. This evidence concerns the gene BRCA1 and Familial prostate cancer.